{"id":454,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/tesamorelin-research-material-vs-egrifta-wr\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"tesamorelin-research-material-vs-egrifta-wr","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/ar\/tesamorelin-research-material-vs-egrifta-wr\/","title":{"rendered":"\u0627\u0644\u0645\u0627\u062f\u0629 \u0627\u0644\u0628\u062d\u062b\u064a\u0629 Tesamorelin \u0645\u0642\u0627\u0628\u0644 EGRIFTA WR: \u0623\u0647\u0645\u064a\u0629 \u0627\u0644\u0635\u064a\u0627\u063a\u0629 \u0648\u0627\u0644\u062d\u0627\u0644\u0629"},"content":{"rendered":"

\u0627\u0633\u0645 \u0627\u0644\u062c\u0632\u064a\u0621 \u0644\u0627 \u064a\u062c\u0639\u0644 \u0645\u0646\u062a\u062c\u064a\u0646 \u0642\u0627\u0628\u0644\u064a\u0646 \u0644\u0644\u062a\u0628\u062f\u064a\u0644. EGRIFTA WR \u0647\u0648 \u062f\u0648\u0627\u0621 \u0646\u0647\u0627\u0626\u064a \u0645\u0639\u062a\u0645\u062f \u0645\u0646 FDA \u0628\u062a\u0631\u0643\u064a\u0628\u0629 \u0645\u062d\u062f\u062f\u0629 \u0648\u0636\u0648\u0627\u0628\u0637 \u062a\u0635\u0646\u064a\u0639 \u0648\u0645\u0639\u0644\u0648\u0645\u0627\u062a \u0648\u0635\u0641\u064a\u0629 \u0648\u0645\u0624\u0634\u0631\u0627\u062a \u0645\u0639\u062a\u0645\u062f\u0629. \u0627\u0644\u0645\u0627\u062f\u0629 \u0627\u0644\u0628\u062d\u062b\u064a\u0629 \u0644\u0640 tesamorelin \u0639\u0628\u0627\u0631\u0629 \u0639\u0646 \u0645\u0642\u0627\u0644\u0629 \u0643\u062a\u0627\u0644\u0648\u062c \u0645\u0646\u0641\u0635\u0644\u0629 \u0645\u062e\u0635\u0635\u0629 \u0644\u0644\u0639\u0645\u0644 \u0627\u0644\u0645\u062e\u062a\u0628\u0631\u064a.<\/p>

\u0627\u0644\u0648\u062c\u0628\u0627\u062a \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0627\u0644\u0631\u0626\u064a\u0633\u064a\u0629<\/h2>
  • \u062a\u0646\u0637\u0628\u0642 \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629 \u0639\u0644\u0649 \u0645\u0646\u062a\u062c \u0646\u0647\u0627\u0626\u064a \u0645\u0639\u064a\u0646 \u0648\u062a\u0637\u0628\u064a\u0642\u060c \u0648\u0644\u064a\u0633 \u0643\u0644 \u0639\u0646\u0635\u0631 \u064a\u0633\u0645\u0649 tesamorelin.<\/li>
  • \u062a\u0639\u062f \u0627\u0644\u062a\u0631\u0643\u064a\u0628\u0629 \u0648\u0627\u0644\u0633\u0648\u0627\u063a\u0627\u062a \u0648\u0627\u0644\u0642\u0648\u0629 \u0648\u0646\u0638\u0627\u0645 \u0627\u0644\u062d\u0627\u0648\u064a\u0629 \u0648\u0628\u064a\u0627\u0646\u0627\u062a \u0627\u0644\u0627\u0633\u062a\u0642\u0631\u0627\u0631 \u062c\u0632\u0621\u064b\u0627 \u0645\u0646 \u0647\u0648\u064a\u0629 \u0627\u0644\u0645\u0646\u062a\u062c.<\/li>
  • \u064a\u062c\u0628 \u0623\u0646 \u062a\u0633\u062a\u0634\u0647\u062f \u0635\u0641\u062d\u0627\u062a \u0627\u0644\u0645\u0648\u0627\u062f \u0627\u0644\u0628\u062d\u062b\u064a\u0629 \u0628\u0627\u0644\u0623\u062f\u0644\u0629 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0643\u0633\u064a\u0627\u0642 \u0645\u0639 \u0631\u0641\u0636 \u0627\u062f\u0639\u0627\u0621\u0627\u062a \u0627\u0644\u062a\u0643\u0627\u0641\u0624 \u0627\u0644\u0639\u0644\u0627\u062c\u064a.<\/li><\/ul><\/div><\/div>
    \"\u0628\u0627\u062d\u062b
    \u0627\u0644\u0631\u0633\u0645 \u0627\u0644\u062a\u0648\u0636\u064a\u062d\u064a \u0627\u0644\u062a\u062d\u0631\u064a\u0631\u064a \u0644\u0644\u0623\u0628\u062d\u0627\u062b \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629\u061b \u0648\u0644\u0627 \u064a\u064f\u0638\u0647\u0631 \u0639\u0628\u0648\u0629 EGRIFTA WR \u0623\u0648 \u0645\u062c\u0645\u0648\u0639\u0629 \u0627\u0644\u0623\u0628\u062d\u0627\u062b \u0627\u0644\u0645\u062a\u0648\u0641\u0631\u0629.<\/figcaption><\/figure>

    \u0627\u0644\u0633\u062c\u0644 \u0627\u0644\u0645\u0639\u062a\u0645\u062f \u062e\u0627\u0635 \u0628\u0627\u0644\u0635\u064a\u0627\u063a\u0629<\/h2>

    \u062a\u0635\u0641 \u0639\u0644\u0627\u0645\u0629 FDA \u0634\u0643\u0644 \u062c\u0631\u0639\u0629 EGRIFTA WR \u0648\u0642\u0648\u0629 \u0627\u0644\u0642\u0627\u0631\u0648\u0631\u0629 \u0648\u0627\u0644\u0645\u062e\u0641\u0641 \u0648\u0627\u0644\u062a\u062e\u0632\u064a\u0646 \u0648\u0627\u0644\u062a\u0639\u0644\u064a\u0645\u0627\u062a \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0627\u0644\u0645\u0646\u062a\u062c. \u0643\u0645\u0627 \u0623\u0646\u0647 \u064a\u0645\u064a\u0632 EGRIFTA WR \u0639\u0646 \u062a\u0631\u0643\u064a\u0628\u0629 \u062a\u064a\u0633\u0627\u0645\u0648\u0631\u064a\u0644\u064a\u0646 \u0623\u062e\u0631\u0649 \u0648\u064a\u0630\u0643\u0631 \u0623\u0646 \u0627\u0644\u062a\u0631\u0643\u064a\u0628\u0627\u062a \u063a\u064a\u0631 \u0642\u0627\u0628\u0644\u0629 \u0644\u0644\u0627\u0633\u062a\u0628\u062f\u0627\u0644. \u0648\u0647\u0630\u0627 \u062f\u0644\u064a\u0644 \u0645\u0628\u0627\u0634\u0631 \u0639\u0644\u0649 \u0633\u0628\u0628 \u0639\u062f\u0645 \u0643\u0641\u0627\u064a\u0629 \u0627\u0633\u0645 \u0627\u0644\u0639\u0646\u0635\u0631 \u0627\u0644\u0646\u0634\u0637 \u0648\u062d\u062f\u0647 \u0644\u062a\u062d\u0642\u064a\u0642 \u0627\u0644\u062a\u0643\u0627\u0641\u0624.<\/p>

    \u062a\u0645\u062a \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629 \u0639\u0644\u0649 \u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0646\u0647\u0627\u0626\u064a<\/strong>\u0635\u064a\u0627\u063a\u0629 \u062e\u0627\u0635\u0629 \u0628\u0627\u0644\u062a\u0637\u0628\u064a\u0642 \u0648\u0648\u0636\u0639 \u0627\u0644\u0639\u0644\u0627\u0645\u0627\u062a \u0648\u0636\u0648\u0627\u0628\u0637 \u0627\u0644\u062a\u0635\u0646\u064a\u0639<\/span><\/div>
    \u0627\u0644\u0645\u0648\u0627\u062f \u0627\u0644\u0628\u062d\u062b\u064a\u0629<\/strong>\u0645\u0648\u0627\u0635\u0641\u0627\u062a \u0627\u0644\u0645\u062e\u062a\u0628\u0631 \u0648\u062a\u0648\u062b\u064a\u0642 \u0627\u0644\u0643\u0645\u064a\u0629\u061b \u0644\u0627 \u064a\u0648\u062c\u062f \u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0628\u0634\u0631\u064a \u0623\u0648 \u0628\u064a\u0637\u0631\u064a<\/span><\/div>
    \u0627\u0644\u0623\u062f\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a<\/strong>\u062a\u0645\u062a \u062f\u0631\u0627\u0633\u0629 \u0627\u0644\u0623\u062f\u0644\u0629 \u0639\u0644\u0649 \u0627\u0644\u062a\u062f\u062e\u0644 \u0648\u0627\u0644\u0628\u0631\u0648\u062a\u0648\u0643\u0648\u0644 \u0628\u0627\u0644\u0641\u0639\u0644<\/span><\/div><\/div><\/div>

    \u0623\u0633\u0626\u0644\u0629 \u062a\u062d\u0644\u064a\u0644\u064a\u0629 \u0644\u0634\u0631\u0627\u0621 \u0627\u0644\u0628\u062d\u0648\u062b<\/h2>

    \u062a\u0623\u0643\u064a\u062f \u0647\u0648\u064a\u0629 \u0627\u0644\u062a\u0633\u0644\u0633\u0644\u060c \u0648\u0627\u0644\u0634\u0643\u0644 \u0627\u0644\u062c\u0632\u064a\u0626\u064a\u060c \u0648\u0637\u0631\u064a\u0642\u0629 \u0627\u0644\u0646\u0642\u0627\u0621\u060c \u0648\u0627\u0644\u062a\u0623\u0643\u064a\u062f \u0627\u0644\u0634\u0627\u0645\u0644\u060c \u0648\u0645\u0639\u0644\u0648\u0645\u0627\u062a \u0627\u0644\u0645\u0627\u0621 \u0648\u0627\u0644\u0645\u0636\u0627\u062f\u0629\u060c \u0648\u0623\u064a \u0634\u0648\u0627\u0626\u0628 \u0623\u0648 \u0645\u062a\u0637\u0644\u0628\u0627\u062a \u062a\u062c\u0645\u064a\u0639 \u062e\u0627\u0635\u0629 \u0628\u0627\u0644\u0645\u0634\u0631\u0648\u0639. \u0642\u0645 \u0628\u0645\u0631\u0627\u062c\u0639\u0629 \u0627\u0644\u0633\u062c\u0644\u0627\u062a \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0627\u0644\u062f\u0641\u0639\u0629 \u0628\u062f\u0644\u0627\u064b \u0645\u0646 \u0627\u0644\u0627\u0639\u062a\u0645\u0627\u062f \u0639\u0644\u0649 \u0645\u0648\u0627\u0635\u0641\u0627\u062a \u0635\u0641\u062d\u0629 \u0627\u0644\u0648\u064a\u0628 \u0648\u062d\u062f\u0647\u0627.<\/p>

    \u0625\u0630\u0627 \u0643\u0627\u0646\u062a \u0627\u0644\u062a\u062c\u0631\u0628\u0629 \u062a\u0647\u062f\u0641 \u0625\u0644\u0649 \u0625\u0639\u0627\u062f\u0629 \u0625\u0646\u062a\u0627\u062c \u0627\u0644\u0639\u0645\u0644 \u0627\u0644\u0645\u0646\u0634\u0648\u0631\u060c \u0642\u0645 \u0628\u062a\u0648\u062b\u064a\u0642 \u0627\u0644\u0627\u062e\u062a\u0644\u0627\u0641\u0627\u062a \u0628\u064a\u0646 \u062a\u062f\u062e\u0644 \u0627\u0644\u0648\u0631\u0642\u0629 \u0648\u0645\u0648\u0627\u062f \u0627\u0644\u0643\u062a\u0627\u0644\u0648\u062c. \u062a\u0628\u062f\u0623 \u0642\u0627\u0628\u0644\u064a\u0629 \u0627\u0644\u062a\u0643\u0631\u0627\u0631 \u0628\u0648\u0635\u0641 \u062a\u0644\u0643 \u0627\u0644\u0627\u062e\u062a\u0644\u0627\u0641\u0627\u062a\u060c \u0648\u0644\u064a\u0633 \u0627\u0641\u062a\u0631\u0627\u0636\u0647\u0627 \u0628\u0639\u064a\u062f\u064b\u0627.<\/p>

    \u0644\u063a\u0629 SEO \u0627\u0644\u062a\u064a \u062a\u0638\u0644 \u062f\u0642\u064a\u0642\u0629 \u0639\u0644\u0645\u064a\u0627<\/h2>

    \u0627\u0633\u062a\u062e\u062f\u0645 \u0639\u0628\u0627\u0631\u0627\u062a \u0645\u062b\u0644 \"\u062f\u0631\u0633 \u0628\u0627\u0633\u0645\" \u0648\"\u062a\u0645 \u0627\u0644\u0625\u0628\u0644\u0627\u063a \u0639\u0646 \u0627\u0644\u062a\u062c\u0631\u0628\u0629\" \u0648\"\u062a\u0634\u064a\u0631 \u0639\u0644\u0627\u0645\u0629 FDA\" \u0645\u0639 \u0627\u0644\u0627\u0633\u062a\u0634\u0647\u0627\u062f\u0627\u062a \u0627\u0644\u0645\u0628\u0627\u0634\u0631\u0629. \u062a\u062c\u0646\u0628 \u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0639\u0628\u0627\u0631\u0629 \"\u064a\u0639\u0645\u0644 \u0645\u0646 \u0623\u062c\u0644\" \u0623\u0648 \"\u064a\u0639\u0627\u0645\u0644\" \u0623\u0648 \"\u064a\u062d\u0631\u0642 \u0627\u0644\u062f\u0647\u0648\u0646\" \u0623\u0648 \"\u064a\u0639\u0627\u062f\u0644\" \u0641\u064a \u0635\u0641\u062d\u0629 \u0627\u0644\u0645\u0648\u0627\u062f \u0627\u0644\u0628\u062d\u062b\u064a\u0629. \u064a\u0645\u0643\u0646 \u0623\u0646 \u064a\u0623\u062a\u064a SEO \u0627\u0644\u0642\u0648\u064a \u0645\u0646 \u0627\u0644\u0627\u0643\u062a\u0645\u0627\u0644 \u0648\u0627\u0644\u0648\u0636\u0648\u062d \u062f\u0648\u0646 \u062a\u062d\u0648\u064a\u0644 \u0627\u0644\u0623\u062f\u0644\u0629 \u0625\u0644\u0649 \u0645\u0637\u0627\u0644\u0628\u0629 \u0645\u0628\u064a\u0639\u0627\u062a \u063a\u064a\u0631 \u0645\u062f\u0639\u0648\u0645\u0629.<\/p>","protected":false},"excerpt":{"rendered":"

    \u0645\u0642\u0627\u0631\u0646\u0629 \u0648\u0627\u0636\u062d\u0629 \u0628\u064a\u0646 \u0627\u0644\u0645\u0627\u062f\u0629 \u0627\u0644\u0628\u062d\u062b\u064a\u0629 \u0627\u0644\u062a\u064a\u0633\u0627\u0645\u0648\u0631\u064a\u0644\u064a\u0646 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0646\u0647\u0627\u0626\u064a EGRIFTA WR \u0627\u0644\u0645\u0639\u062a\u0645\u062f \u0645\u0646 FDA\u060c \u0645\u0639 \u0627\u0644\u062a\u0631\u0643\u064a\u0632 \u0639\u0644\u0649 \u0627\u0644\u0635\u064a\u0627\u063a\u0629 \u0648\u0627\u0644\u062a\u0648\u062b\u064a\u0642 \u0648\u0646\u0642\u0644 \u0627\u0644\u0623\u062f\u0644\u0629.<\/p>","protected":false},"author":1,"featured_media":624,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"367","pim_article_type":"Regulatory and formulation boundary","pim_evidence_level":"FDA labeling and analytical quality principles","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-27","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"FDA EGRIFTA WR prescribing information\",\"url\":\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/022505s020lbl.pdf\",\"note\":\"Formulation-specific approved label and non-substitutability language.\"},{\"title\":\"Randomized tesamorelin trial in HIV-associated abdominal fat accumulation\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20101189\/\",\"note\":\"Clinical evidence context.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-454","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"\nTesamorelin Research Material vs EGRIFTA WR: Why Formulation and Status Matter - NHD<\/title>\n<meta name=\"description\" content=\"A clear comparison between a tesamorelin research material and the FDA-approved EGRIFTA WR finished drug, focusing on formulation, documentation and evidence transfer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/ar\/tesamorelin-research-material-vs-egrifta-wr\/\" \/>\n<meta property=\"og:locale\" content=\"ar_AR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tesamorelin Research Material vs EGRIFTA WR: Why Formulation and Status Matter\" \/>\n<meta property=\"og:description\" content=\"A clear comparison between a tesamorelin research material and the FDA-approved EGRIFTA WR finished drug, focusing on formulation, documentation and evidence transfer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/ar\/tesamorelin-research-material-vs-egrifta-wr\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-research-material-vs-egrifta-wr-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631\" \/>\n\t<meta name=\"twitter:data2\" content=\"\u062f\u0642\u064a\u0642\u0629 \u0648\u0627\u062d\u062f\u0629\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-research-material-vs-egrifta-wr\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-research-material-vs-egrifta-wr\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Tesamorelin Research Material vs EGRIFTA WR: Why Formulation and Status Matter\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-research-material-vs-egrifta-wr\\\/\"},\"wordCount\":311,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-research-material-vs-egrifta-wr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tesamorelin-research-material-vs-egrifta-wr-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-research-material-vs-egrifta-wr\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-research-material-vs-egrifta-wr\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-research-material-vs-egrifta-wr\\\/\",\"name\":\"Tesamorelin Research Material vs EGRIFTA WR: Why Formulation and Status Matter - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-research-material-vs-egrifta-wr\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-research-material-vs-egrifta-wr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tesamorelin-research-material-vs-egrifta-wr-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"A clear comparison between a tesamorelin research material and the FDA-approved EGRIFTA WR finished drug, focusing on formulation, documentation and evidence transfer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-research-material-vs-egrifta-wr\\\/#breadcrumb\"},\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-research-material-vs-egrifta-wr\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-research-material-vs-egrifta-wr\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tesamorelin-research-material-vs-egrifta-wr-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tesamorelin-research-material-vs-egrifta-wr-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-research-material-vs-egrifta-wr\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tesamorelin Research Material vs EGRIFTA WR: Why Formulation and Status Matter\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ar\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/ar\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"\u0627\u0644\u0645\u0627\u062f\u0629 \u0627\u0644\u0628\u062d\u062b\u064a\u0629 Tesamorelin \u0645\u0642\u0627\u0628\u0644 EGRIFTA WR: \u0623\u0647\u0645\u064a\u0629 \u0627\u0644\u0635\u064a\u0627\u063a\u0629 \u0648\u0627\u0644\u062d\u0627\u0644\u0629 - NHD","description":"\u0645\u0642\u0627\u0631\u0646\u0629 \u0648\u0627\u0636\u062d\u0629 \u0628\u064a\u0646 \u0627\u0644\u0645\u0627\u062f\u0629 \u0627\u0644\u0628\u062d\u062b\u064a\u0629 \u0627\u0644\u062a\u064a\u0633\u0627\u0645\u0648\u0631\u064a\u0644\u064a\u0646 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0646\u0647\u0627\u0626\u064a EGRIFTA WR \u0627\u0644\u0645\u0639\u062a\u0645\u062f \u0645\u0646 FDA\u060c \u0645\u0639 \u0627\u0644\u062a\u0631\u0643\u064a\u0632 \u0639\u0644\u0649 \u0627\u0644\u0635\u064a\u0627\u063a\u0629 \u0648\u0627\u0644\u062a\u0648\u062b\u064a\u0642 \u0648\u0646\u0642\u0644 \u0627\u0644\u0623\u062f\u0644\u0629.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/ar\/tesamorelin-research-material-vs-egrifta-wr\/","og_locale":"ar_AR","og_type":"article","og_title":"Tesamorelin Research Material vs EGRIFTA WR: Why Formulation and Status Matter","og_description":"A clear comparison between a tesamorelin research material and the FDA-approved EGRIFTA WR finished drug, focusing on formulation, documentation and evidence transfer.","og_url":"https:\/\/nhdbio.com\/ar\/tesamorelin-research-material-vs-egrifta-wr\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-research-material-vs-egrifta-wr-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629":"NHD Technical Team","\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631":"\u062f\u0642\u064a\u0642\u0629 \u0648\u0627\u062d\u062f\u0629"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/tesamorelin-research-material-vs-egrifta-wr\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/tesamorelin-research-material-vs-egrifta-wr\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Tesamorelin Research Material vs EGRIFTA WR: Why Formulation and Status Matter","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/tesamorelin-research-material-vs-egrifta-wr\/"},"wordCount":311,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/tesamorelin-research-material-vs-egrifta-wr\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-research-material-vs-egrifta-wr-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"ar","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/tesamorelin-research-material-vs-egrifta-wr\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/tesamorelin-research-material-vs-egrifta-wr\/","url":"https:\/\/nhdbio.com\/tesamorelin-research-material-vs-egrifta-wr\/","name":"\u0627\u0644\u0645\u0627\u062f\u0629 \u0627\u0644\u0628\u062d\u062b\u064a\u0629 Tesamorelin \u0645\u0642\u0627\u0628\u0644 EGRIFTA WR: \u0623\u0647\u0645\u064a\u0629 \u0627\u0644\u0635\u064a\u0627\u063a\u0629 \u0648\u0627\u0644\u062d\u0627\u0644\u0629 - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/tesamorelin-research-material-vs-egrifta-wr\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/tesamorelin-research-material-vs-egrifta-wr\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-research-material-vs-egrifta-wr-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"\u0645\u0642\u0627\u0631\u0646\u0629 \u0648\u0627\u0636\u062d\u0629 \u0628\u064a\u0646 \u0627\u0644\u0645\u0627\u062f\u0629 \u0627\u0644\u0628\u062d\u062b\u064a\u0629 \u0627\u0644\u062a\u064a\u0633\u0627\u0645\u0648\u0631\u064a\u0644\u064a\u0646 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0646\u0647\u0627\u0626\u064a EGRIFTA WR \u0627\u0644\u0645\u0639\u062a\u0645\u062f \u0645\u0646 FDA\u060c \u0645\u0639 \u0627\u0644\u062a\u0631\u0643\u064a\u0632 \u0639\u0644\u0649 \u0627\u0644\u0635\u064a\u0627\u063a\u0629 \u0648\u0627\u0644\u062a\u0648\u062b\u064a\u0642 \u0648\u0646\u0642\u0644 \u0627\u0644\u0623\u062f\u0644\u0629.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/tesamorelin-research-material-vs-egrifta-wr\/#breadcrumb"},"inLanguage":"ar","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/tesamorelin-research-material-vs-egrifta-wr\/"]}]},{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nhdbio.com\/tesamorelin-research-material-vs-egrifta-wr\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-research-material-vs-egrifta-wr-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-research-material-vs-egrifta-wr-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/tesamorelin-research-material-vs-egrifta-wr\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Tesamorelin Research Material vs EGRIFTA WR: Why Formulation and Status Matter"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"\u0645\u0648\u0627\u062f \u062e\u0627\u0645 \u0628\u0628\u062a\u064a\u062f\u064a\u0629 \u0648\u062a\u062e\u0644\u064a\u0642 \u0627\u0644\u0628\u0628\u062a\u064a\u062f\u0627\u062a \u062d\u0633\u0628 \u0627\u0644\u0637\u0644\u0628","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ar"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"\u0627\u0644\u0641\u0631\u064a\u0642 \u0627\u0644\u0641\u0646\u064a NHD","image":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"\u064a\u062d\u062a\u0641\u0638 \u0641\u0631\u064a\u0642 NHD \u0627\u0644\u0641\u0646\u064a \u0628\u0648\u062b\u0627\u0626\u0642 \u0643\u062a\u0627\u0644\u0648\u062c \u0627\u0644\u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0627\u0644\u0628\u062d\u062b\u064a \u0648\u0645\u0644\u062e\u0635\u0627\u062a \u0627\u0644\u0623\u062f\u0644\u0629. \u062a\u0631\u062a\u0628\u0637 \u0627\u0644\u0645\u0642\u0627\u0644\u0627\u062a \u0627\u0644\u062a\u064a \u062a\u0645\u062a \u0645\u0631\u0627\u062c\u0639\u062a\u0647\u0627 \u0628\u0627\u0644\u0623\u0648\u0631\u0627\u0642 \u0627\u0644\u062a\u064a \u062a\u0645\u062a \u0645\u0631\u0627\u062c\u0639\u062a\u0647\u0627 \u0645\u0646 \u0642\u0628\u0644 \u0627\u0644\u0646\u0638\u0631\u0627\u0621\u060c \u0648\u0633\u062c\u0644\u0627\u062a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0648\u0627\u0644\u0633\u062c\u0644\u0627\u062a \u0627\u0644\u062a\u0646\u0638\u064a\u0645\u064a\u0629\u060c \u0648\u062a\u062d\u062a\u0641\u0638 \u0628\u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0641\u0627\u0631\u063a\u0629 \u0648\u0642\u064a\u0648\u062f \u0627\u0644\u062f\u0631\u0627\u0633\u0629\u060c \u0648\u062a\u0645\u064a\u0632 \u0627\u0644\u062a\u062f\u062e\u0644\u0627\u062a \u0627\u0644\u0645\u0646\u0634\u0648\u0631\u0629 \u0639\u0646 \u0645\u0648\u0627\u062f \u0627\u0644\u0643\u062a\u0627\u0644\u0648\u062c. \u064a\u0645\u0643\u0646 \u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0627\u0644\u0635\u064a\u0627\u063a\u0629 \u0628\u0645\u0633\u0627\u0639\u062f\u0629 AI \u0644\u0644\u0647\u064a\u0643\u0644\u061b \u062a\u0638\u0644 \u0631\u0648\u0627\u0628\u0637 \u0627\u0644\u0645\u0635\u062f\u0631 \u0648\u062d\u062f\u0648\u062f \u0627\u0644\u0623\u062f\u0644\u0629 \u0645\u0631\u0626\u064a\u0629. \u0647\u0630\u0627 \u0627\u0644\u0639\u0645\u0644 \u0644\u064a\u0633 \u0645\u0631\u0627\u062c\u0639\u0629 \u0623\u0642\u0631\u0627\u0646 \u0645\u0633\u062a\u0642\u0644\u0629 \u0623\u0648 \u0646\u0635\u064a\u062d\u0629 \u0637\u0628\u064a\u0629.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/ar\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/posts\/454","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/comments?post=454"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/posts\/454\/revisions"}],"predecessor-version":[{"id":517,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/posts\/454\/revisions\/517"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/media\/624"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/media?parent=454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/categories?post=454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/tags?post=454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}